Spravato (Esketamine)

Spravato (esketamine) is a prescription nasal spray used alongside an oral antidepressant to treat adults with treatment-resistant depression (TRD) and depressive symptoms in adults with major depressive disorder (MDD) experiencing acute suicidal ideation or behavior. Derived from ketamine, known for its rapid antidepressant effects, Spravato acts on the N-methyl-D-aspartate (NMDA) receptor in the brain to restore synaptic connections in mood-regulating regions, alleviating symptoms faster than traditional antidepressants.

Indicated for patients who have not responded adequately to at least two antidepressants, Spravato is administered under healthcare supervision in certified treatment centers due to its potential for abuse and serious side effects. Initially administered twice weekly for four weeks, followed by weekly doses, it can rapidly reduce depressive symptoms within hours to days and provide sustained relief with continued use. Common side effects include dissociation, dizziness, nausea, sedation, and increased blood pressure.

Spravato's availability through a Risk Evaluation and Mitigation Strategy (REMS) program ensures careful patient monitoring and administration. It represents a significant advance for TRD and acute depressive symptoms with suicidal ideation, offering quick and sustained improvement in mood and functioning when used adjunctively with oral antidepressants under strict medical oversight.

Explore Spravato

(esketamine) at our clinic

A breakthrough treatment for adults with treatment-resistant depression (TRD) and acute depressive symptoms, including suicidal thoughts. Derived from ketamine, Spravato swiftly targets mood-regulating brain receptors, providing relief where traditional antidepressants have fallen short.